{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T18:52:12Z","timestamp":1740163932532,"version":"3.37.3"},"reference-count":24,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,10,28]],"date-time":"2022-10-28T00:00:00Z","timestamp":1666915200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,10,28]],"date-time":"2022-10-28T00:00:00Z","timestamp":1666915200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100013302","name":"King Abdullah International Medical Research Center","doi-asserted-by":"publisher","award":["RC15\/142\/R"],"award-info":[{"award-number":["RC15\/142\/R"]}],"id":[{"id":"10.13039\/501100013302","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Animal and human data indicate variable effects of interferons in treating coronavirus infections according to inflammatory status and timing of therapy. In this sub-study of the MIRACLE trial (MERS-CoV Infection Treated with a Combination of Lopinavir\u2013Ritonavir and Interferon \u03b2-1b), we evaluated the heterogeneity of treatment effect of interferon-\u03b21b and lopinavir\u2013ritonavir versus placebo among hospitalized patients with MERS on 90-day mortality, according to cytokine levels and timing of therapy. We measured plasma levels of 17 cytokines at enrollment and tested the treatment effect on 90-day mortality according to cytokine levels (higher versus lower levels using the upper tertile (67%) as a cutoff point) and time to treatment (\u2264\u20097\u00a0days versus\u2009&gt;\u20097\u00a0days of symptom onset) using interaction tests. Among 70 included patients, 32 received interferon-\u03b21b and lopinavir\u2013ritonavir and 38 received placebo. Interferon-\u03b21b and lopinavir\u2013ritonavir reduced mortality in patients with lower IL-2, IL-8 and IL-13 plasma concentrations but not in patients with higher levels (p-value for interaction\u2009=\u20090.09, 0.07, and 0.05, respectively) and with early but not late therapy (p\u2009=\u20090.002). There was no statistically significant heterogeneity of treatment effect according to other cytokine levels.  Further work is needed to evaluate whether the assessment of inflammatory status can help in identifying patients with MERS who may benefit from interferon-\u03b21b and lopinavir\u2013ritonavir.\n<\/jats:p><jats:p>Trial registration: This is a sub-study of the MIRACLE trial (ClinicalTrials.gov number, NCT02845843).<\/jats:p>","DOI":"10.1038\/s41598-022-22742-8","type":"journal-article","created":{"date-parts":[[2022,10,28]],"date-time":"2022-10-28T17:06:30Z","timestamp":1666976790000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Heterogeneity of treatment effect of interferon-\u03b21b and lopinavir\u2013ritonavir in patients with Middle East respiratory syndrome by cytokine levels"],"prefix":"10.1038","volume":"12","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5735-6241","authenticated-orcid":false,"given":"Yaseen M.","family":"Arabi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ayed Y.","family":"Asiri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Abdullah M.","family":"Assiri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mashan L.","family":"Abdullah","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Haya A.","family":"Aljami","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hanan H.","family":"Balkhy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Majed","family":"Al Jeraisy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yasser","family":"Mandourah","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sameera","family":"AlJohani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shmeylan","family":"Al Harbi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hani A. Aziz","family":"Jokhdar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ahmad M.","family":"Deeb","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ziad A.","family":"Memish","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jesna","family":"Jose","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sameeh","family":"Ghazal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sarah","family":"Al Faraj","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ghaleb A.","family":"Al Mekhlafi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nisreen Murad","family":"Sherbeeni","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fatehi Elnour","family":"Elzein","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Frederick G.","family":"Hayden","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert A.","family":"Fowler","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Badriah M.","family":"AlMutairi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Abdulaziz","family":"Al-Dawood","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Naif Khalaf","family":"Alharbi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2022,10,28]]},"reference":[{"key":"22742_CR1","doi-asserted-by":"publisher","first-page":"584","DOI":"10.1056\/NEJMsr1408795","volume":"376","author":"YM Arabi","year":"2017","unstructured":"Arabi, Y. M. et al. Middle East Respiratory Syndrome. N. Engl. J. Med. 376, 584\u2013594. https:\/\/doi.org\/10.1056\/NEJMsr1408795 (2017).","journal-title":"N. Engl. J. Med."},{"key":"22742_CR2","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1111\/zph.12816","volume":"68","author":"MG Hemida","year":"2021","unstructured":"Hemida, M. G., Ali, A. M. & Alnaeem, A. The Middle East respiratory syndrome coronavirus (MERS-CoV) nucleic acids detected in the saliva and conjunctiva of some naturally infected dromedary camels in Saudi Arabia -2019. Zoonoses Public Health 68, 353\u2013357. https:\/\/doi.org\/10.1111\/zph.12816 (2021).","journal-title":"Zoonoses Public Health"},{"key":"22742_CR3","doi-asserted-by":"publisher","first-page":"1215","DOI":"10.3390\/v12111215","volume":"12","author":"TA Aljasim","year":"2020","unstructured":"Aljasim, T. A. et al. High rate of circulating MERS-CoV in dromedary camels at slaughterhouses in Riyadh, 2019. Viruses 12, 1215. https:\/\/doi.org\/10.3390\/v12111215 (2020).","journal-title":"Viruses"},{"key":"22742_CR4","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1097\/CCM.0000000000004724","volume":"49","author":"YM Arabi","year":"2021","unstructured":"Arabi, Y. M. et al. Inflammatory response and phenotyping in severe acute respiratory infection from the Middle East respiratory syndrome coronavirus and other etiologies. Crit. Care Med. 49, 228\u2013239. https:\/\/doi.org\/10.1097\/CCM.0000000000004724 (2021).","journal-title":"Crit. Care Med."},{"key":"22742_CR5","doi-asserted-by":"publisher","first-page":"3625","DOI":"10.1172\/JCI126363","volume":"129","author":"R Channappanavar","year":"2019","unstructured":"Channappanavar, R. et al. IFN-I response timing relative to virus replication determines MERS coronavirus infection outcomes. J. Clin. Invest. 129, 3625\u20133639. https:\/\/doi.org\/10.1172\/JCI126363 (2019).","journal-title":"J. Clin. Invest."},{"key":"22742_CR6","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1016\/j.chom.2016.01.007","volume":"19","author":"R Channappanavar","year":"2016","unstructured":"Channappanavar, R. et al. Dysregulated type I interferon and inflammatory monocyte-macrophage responses cause lethal pneumonia in SARS-CoV-infected mice. Cell Host Microbe 19, 181\u2013193. https:\/\/doi.org\/10.1016\/j.chom.2016.01.007 (2016).","journal-title":"Cell Host Microbe"},{"key":"22742_CR7","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1186\/s13063-019-3846-x","volume":"21","author":"YM Arabi","year":"2020","unstructured":"Arabi, Y. M. et al. Treatment of Middle East respiratory syndrome with a combination of lopinavir\/ritonavir and interferon-\u03b21b (MIRACLE trial): Statistical analysis plan for a recursive two-stage group sequential randomized controlled trial. Trials 21, 8. https:\/\/doi.org\/10.1186\/s13063-019-3846-x (2020).","journal-title":"Trials"},{"key":"22742_CR8","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1186\/s13063-017-2427-0","volume":"19","author":"YM Arabi","year":"2018","unstructured":"Arabi, Y. M. et al. Treatment of Middle East Respiratory Syndrome with a combination of lopinavir-ritonavir and interferon-\u03b21b (MIRACLE trial): Study protocol for a randomized controlled trial. Trials 19, 81. https:\/\/doi.org\/10.1186\/s13063-017-2427-0 (2018).","journal-title":"Trials"},{"key":"22742_CR9","doi-asserted-by":"publisher","first-page":"1645","DOI":"10.1056\/NEJMoa2015294","volume":"383","author":"YM Arabi","year":"2020","unstructured":"Arabi, Y. M. et al. Interferon Beta-1b and lopinavir-ritonavir for Middle East respiratory syndrome. N. Engl. J. Med. 383, 1645\u20131656. https:\/\/doi.org\/10.1056\/NEJMoa2015294 (2020).","journal-title":"N. Engl. J. Med."},{"key":"22742_CR10","doi-asserted-by":"publisher","first-page":"1717","DOI":"10.3346\/jkms.2016.31.11.1717","volume":"31","author":"ES Kim","year":"2016","unstructured":"Kim, E. S. et al. Clinical progression and cytokine profiles of Middle East respiratory syndrome coronavirus infection. J. Korean Med. Sci. 31, 1717\u20131725. https:\/\/doi.org\/10.3346\/jkms.2016.31.11.1717 (2016).","journal-title":"J. Korean Med. Sci."},{"key":"22742_CR11","doi-asserted-by":"publisher","first-page":"984","DOI":"10.1093\/cid\/ciy595","volume":"68","author":"HS Shin","year":"2019","unstructured":"Shin, H. S. et al. Immune responses to Middle East respiratory syndrome coronavirus during the acute and convalescent phases of human infection. Clin. Infect. Dis. 68, 984\u2013992. https:\/\/doi.org\/10.1093\/cid\/ciy595 (2019).","journal-title":"Clin. Infect. Dis."},{"key":"22742_CR12","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1016\/j.cyto.2018.01.025","volume":"104","author":"WH Mahallawi","year":"2018","unstructured":"Mahallawi, W. H., Khabour, O. F., Zhang, Q., Makhdoum, H. M. & Suliman, B. A. MERS-CoV infection in humans is associated with a pro-inflammatory Th1 and Th17 cytokine profile. Cytokine 104, 8\u201313. https:\/\/doi.org\/10.1016\/j.cyto.2018.01.025 (2018).","journal-title":"Cytokine"},{"key":"22742_CR13","doi-asserted-by":"publisher","first-page":"2679","DOI":"10.1099\/vir.0.055533-0","volume":"94","author":"SKP Lau","year":"2013","unstructured":"Lau, S. K. P. et al. Delayed induction of proinflammatory cytokines and suppression of innate antiviral response by the novel Middle East respiratory syndrome coronavirus: Implications for pathogenesis and treatment. J. Gen. Virol. 94, 2679\u20132690. https:\/\/doi.org\/10.1099\/vir.0.055533-0 (2013).","journal-title":"J. Gen. Virol."},{"key":"22742_CR14","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0088716","volume":"9","author":"E Faure","year":"2014","unstructured":"Faure, E. et al. Distinct immune response in two MERS-CoV-infected patients: Can we go from bench to bedside?. PLoS ONE 9, e88716. https:\/\/doi.org\/10.1371\/journal.pone.0088716 (2014).","journal-title":"PLoS ONE"},{"key":"22742_CR15","doi-asserted-by":"publisher","first-page":"264","DOI":"10.1016\/j.coviro.2012.04.004","volume":"2","author":"AL Totura","year":"2012","unstructured":"Totura, A. L. & Baric, R. S. SARS coronavirus pathogenesis: Host innate immune responses and viral antagonism of interferon. Curr. Opin. Virol. 2, 264\u2013275. https:\/\/doi.org\/10.1016\/j.coviro.2012.04.004 (2012).","journal-title":"Curr. Opin. Virol."},{"key":"22742_CR16","doi-asserted-by":"publisher","first-page":"87","DOI":"10.3851\/IMP2792","volume":"20","author":"M Khalid","year":"2015","unstructured":"Khalid, M. et al. Ribavirin and interferon-alpha2b as primary and preventive treatment for Middle East respiratory syndrome coronavirus: A preliminary report of two cases. Antivir. Ther. 20, 87\u201391. https:\/\/doi.org\/10.3851\/IMP2792 (2015).","journal-title":"Antivir. Ther."},{"key":"22742_CR17","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1016\/j.ijid.2013.12.003","volume":"20","author":"JA Al-Tawfiq","year":"2014","unstructured":"Al-Tawfiq, J. A., Momattin, H., Dib, J. & Memish, Z. A. Ribavirin and interferon therapy in patients infected with the Middle East respiratory syndrome coronavirus: An observational study. Int.J. Infect. Dis. 20, 42\u201346. https:\/\/doi.org\/10.1016\/j.ijid.2013.12.003 (2014).","journal-title":"Int.J. Infect. Dis."},{"key":"22742_CR18","doi-asserted-by":"publisher","first-page":"2129","DOI":"10.1093\/jac\/dkv085","volume":"70","author":"S Shalhoub","year":"2015","unstructured":"Shalhoub, S. et al. IFN-alpha2a or IFN-beta1a in combination with ribavirin to treat Middle East respiratory syndrome coronavirus pneumonia: A retrospective study. J. Antimicrob. Chemother. 70, 2129\u20132132. https:\/\/doi.org\/10.1093\/jac\/dkv085 (2015).","journal-title":"J. Antimicrob. Chemother."},{"key":"22742_CR19","doi-asserted-by":"publisher","first-page":"1090","DOI":"10.1016\/s1473-3099(14)70920-x","volume":"14","author":"AS Omrani","year":"2014","unstructured":"Omrani, A. S. et al. Ribavirin and interferon alfa-2a for severe Middle East respiratory syndrome coronavirus infection: A retrospective cohort study. Lancet. Infect. Dis 14, 1090\u20131095. https:\/\/doi.org\/10.1016\/s1473-3099(14)70920-x (2014).","journal-title":"Lancet. Infect. Dis"},{"key":"22742_CR20","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciz544","author":"YM Arabi","year":"2019","unstructured":"Arabi, Y. M. et al. Ribavirin and interferon therapy for critically ill patients with Middle East respiratory syndrome: A multicenter observational study. Clin. Infect. Dis. https:\/\/doi.org\/10.1093\/cid\/ciz544 (2019).","journal-title":"Clin. Infect. Dis."},{"key":"22742_CR21","doi-asserted-by":"publisher","first-page":"611","DOI":"10.1016\/S2213-2600(14)70097-9","volume":"2","author":"CS Calfee","year":"2014","unstructured":"Calfee, C. S. et al. Subphenotypes in acute respiratory distress syndrome: Latent class analysis of data from two randomised controlled trials. Lancet Respir. Med. 2, 611\u2013620. https:\/\/doi.org\/10.1016\/S2213-2600(14)70097-9 (2014).","journal-title":"Lancet Respir. Med."},{"key":"22742_CR22","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1164\/rccm.201603-0645OC","volume":"195","author":"KR Famous","year":"2017","unstructured":"Famous, K. R. et al. Acute respiratory distress syndrome subphenotypes respond differently to randomized fluid management strategy. Am. J. Respir. Crit. Care Med. 195, 331\u2013338. https:\/\/doi.org\/10.1164\/rccm.201603-0645OC (2017).","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"22742_CR23","doi-asserted-by":"publisher","first-page":"691","DOI":"10.1016\/S2213-2600(18)30177-2","volume":"6","author":"CS Calfee","year":"2018","unstructured":"Calfee, C. S. et al. Acute respiratory distress syndrome subphenotypes and differential response to simvastatin: Secondary analysis of a randomised controlled trial. Lancet Respir. Med. 6, 691\u2013698. https:\/\/doi.org\/10.1016\/S2213-2600(18)30177-2 (2018).","journal-title":"Lancet Respir. Med."},{"key":"22742_CR24","doi-asserted-by":"publisher","DOI":"10.1007\/s00134-018-5378-3","author":"P Sinha","year":"2018","unstructured":"Sinha, P. et al. Latent class analysis of ARDS subphenotypes: A secondary analysis of the statins for acutely injured lungs from sepsis (SAILS) study. Intensive Care Med. https:\/\/doi.org\/10.1007\/s00134-018-5378-3 (2018).","journal-title":"Intensive Care Med."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-022-22742-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-022-22742-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-022-22742-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,10,28]],"date-time":"2022-10-28T17:21:29Z","timestamp":1666977689000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-022-22742-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,10,28]]},"references-count":24,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,12]]}},"alternative-id":["22742"],"URL":"https:\/\/doi.org\/10.1038\/s41598-022-22742-8","relation":{},"ISSN":["2045-2322"],"issn-type":[{"type":"electronic","value":"2045-2322"}],"subject":[],"published":{"date-parts":[[2022,10,28]]},"assertion":[{"value":"20 April 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 October 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 October 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"YA is a Board Member of the International Severe Acute Respiratory and Emerging Infection Consortium (ISARIC). FGH is a nonpaid consultant on therapeutics for MERS-CoV and\/or SARS-CoV-2 for Aphrodite\/Daewoong, Appili, Arcturus, Atea, Cidara, Fujifilm, Gilead Sciences, GlaxoSmithKline, Merck, Pardes Biosciences, Pfizer, Primmune, Regeneron, Ridgeback, Roche\/Genentech, SAB Biotherapeutics, Shin Poong Pharm, Takeda, and Vir. He served as member of a COVID-19 therapeutic trial DSMB for CytoDyn with payments to the University of Virginia. Other authors declared that they have no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"18186"}}